Acute Respiratory Distress Syndrome (ARDS) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Acute Respiratory Distress Syndrome (ARDS) Emerging Therapy and TPP Insights

Thelansis's "Acute Respiratory Distress Syndrome (ARDS) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Acute Respiratory Distress Syndrome (ARDS) Overview

Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening inflammatory lung condition characterized by acute, non-cardiogenic pulmonary edema resulting from disruption of the alveolar-capillary barrier. This leads to diffuse alveolar damage (DAD), impaired gas exchange, and refractory hypoxemia.

ARDS typically arises as a complication of direct pulmonary insults (e.g., severe pneumonia, aspiration) or indirect systemic conditions such as Sepsis and major trauma. The pathophysiology is driven by an uncontrolled inflammatory cascade, leading to increased vascular permeability, alveolar flooding, and loss of lung compliance.

Diagnosis and severity classification are based on the Berlin Definition, which stratifies ARDS into mild, moderate, and severe categories according to the degree of hypoxemia (PaO2/FiO2 ratio) and the presence of bilateral infiltrates not explained by cardiac failure or fluid overload.

There are currently no approved targeted pharmacological therapies for ARDS, and management remains entirely supportive. Standard of care relies on lung-protective mechanical ventilation strategies (low tidal volume, optimized PEEP), conservative fluid management, and prevention of ventilator-induced lung injury (VILI). In severe cases, advanced interventions such as prone positioning, neuromuscular blockade, and venovenous extracorporeal membrane oxygenation (VV-ECMO) are utilized to improve oxygenation and survival outcomes.

Key Highlights

• In the US, incident ARDS cases are projected to increase from 547.3K in 2025 to 586.7K by 2035, reflecting a modest growth trajectory (0.7% CAGR) linked to aging population and rising critical illness incidence.
• Despite high incidence, treatment remains entirely supportive, with no approved disease-modifying therapies, representing a major unmet clinical need.
• Increasing research focus on anti-inflammatory, endothelial-stabilizing, and regenerative therapies is expected to shape future treatment paradigms.

Market Overview

• The ARDS market in Italy is projected to grow from $62M in 2025 to $122M by 2035, reflecting moderate-to-strong growth driven by critical care advancements and supportive therapy utilization.
• Market growth is not directly correlated with incidence alone but influenced by:
• Increased use of advanced ICU interventions (e.g., ECMO, ventilation technologies)
• Rising healthcare expenditure in critical care settings
• Current market value is largely derived from supportive care infrastructure (ventilation systems, ICU management), rather than pharmacological therapies.
• Future market expansion will depend on the development and adoption of targeted therapies addressing the underlying inflammatory and vascular mechanisms of ARDS.

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Changchun Tuohua Pharmaceutical Co., Ltd.
• Breathe Biologics, Inc.
• Staidson (Beijing) Biopharmaceuticals Co., Ltd.
• EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
• HTIC, Inc
• BioAegis Therapeutics Inc.
• Direct Biologics, LLC
• Implicit Bioscience
• Dompe Farmaceutici S.p.A
• Pharmazz, Inc.
• Aqualung Therapeutics Corp.
• Arch Biopartners Inc.
• Vasomune Therapeutics, Inc.
• ImmunityBio, Inc.
• AVM Biotechnology Inc"